anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ANTIBODY-DRUG CONJUGATES        The science of pharmaceutical chemistry has progressively provided more and more specific and potent drugs for the treatment and prevention of illnesses. However, until quite recently, there has been no means to direct a drug to the specific part of the body where it is needed.  Thus, although it is often possible to treat a patient with a drug which has the specific effect which is needed, and no other effect  on the body, it is still necessary to administer a whole-body dose.  On the other hand, if it were possible to direct a drug to the organ, tissue or even cell in need of the treatment, it would often be possible to administer an extremely small total dose, since the drug would concentrate itself where it is needed.  The advantage in safety to the patient and economy of the drug is obvious.          For some years now, the science of immunology has been attempting to provide such targeted treatments, by conjugating drugs with antibodies which are directed to specific antigens associated with the locations where the drug is needed.  Patents and scientific articles concerning such antibody-drug conjugates are now numerous.  However, up to the present time, no antibody-drug conjugate is approved for therapeutic use.          The present invention provides a physiologically acceptable drug conjugate of Formula I
PURPOSE: To obtain the subject 1st agent capable of protecting the hair from the heat from a flatiron when used in flatiron perming and of extraordinarily improving the hair's touch feeling, by formulating shellac in a system containing both higher alcohol and reducing gent. CONSTITUTION: This 1st agent for permanent wave is used for flatiron perming to make waves on the hair with a hair grooming flatiron, comprising shellac, a higher alcohol and a reducing agent. The shellac is a resin secreted by Coccus lacca, Tachardia lacca, Laccifer lacca, being parasitic on trees as a result of their sucking of sap. The amount of the shellac to be used is pref. 0.001-1wt.% in the 1st agent. The higher alcohol is e.g. lauryl alcohol, myristy alcohol, cetanol, cetostearyl alcohol, and the reducing agent is e.g. thioglycolic acid, a salt thereof, cysteine, acetyl cysteine. This 1st agent is protective for the hair from heat, giving firm waves to the hair without injuring it and also imparting the hair with favorable touch and luster.
Period 1: Participants receive MK-6552 Treatment B single dose administered orally under fasted conditions (Period 1 = 4 days). Period 2: Participants receive MK-6552 Treatment C single dose administered orally under fasted conditions (Period 2 = 4 days). Period 3: Participants receive MK-6552 Treatment A single dose administered orally under fasted conditions. (Period 3 = 4 days). Period 4: Participants receive MK-6552 Treatment B single dose administered orally under fed conditions (Period 4 = 4 days). Period 5: Participants receive MK-6552 Treatment C single dose administered orally under fed conditions (Period 5 = 4 days). There will be a minimum 3-day washout between periods.
BACKGROUND: Suicide remains a significant global public health challenge, with hanging as the most prevalent suicide method in South Korea. This study aimed to determine diagnostic markers confirming suicidal hanging-associated deaths.
METHODS: In this prospective study, hemorrhages at the periosteal-clavicular origin of the sternocleidomastoid (SCM) muscles were compared among suicidal hanging, manual strangulation, and ligature strangulation cases. This study included 211 cases of suicide by hanging, and a control group of 50 individuals who underwent cardiopulmonary resuscitation but died of other causes. Additionally, nine cases of ligature strangulation and six cases of manual strangulation were analyzed. Postmortem examinations were conducted, and clavicular hemorrhages were histologically evaluated. Statistical analyses were performed using the χ² test.
RESULTS: Hemorrhages at the periosteal-clavicular origin of the SCM were observed in 178 of the 211 hanging cases (84.4%). The highest frequency of clavicular hemorrhage was found in typical hanging cases with complete suspension. Among the 50 control cases, only three showed hemorrhages in the clavicular region, but these were extravasations in the adjoining soft tissue, not in the periosteum. In cases of manual and ligature strangulation, SCM hemorrhages were found within the muscle tissue and were not of periosteal-clavicular origin.
CONCLUSION: Hemorrhage at the periosteal-clavicular origin of the SCM is a significant finding in suicidal hanging and serves as a potential pathognomonic marker for confirming cases of suicidal hanging. The study revealed a statistically significant association between the type of hanging, completeness of body suspension, and the occurrence of these hemorrhages. Cardiopulmonary resuscitation does not cause a hemorrhage at this location.
ARM A: Azacitidine 75 mg/m\^2/day by vein over 15 - 30 minutes daily for 5 days (Days 1 - 5). Vorinostat 200 mg by mouth three time a day with food for 5 days (Days 1 - 5). Courses repeated every 3 to 8 weeks.
Tranexamic acid tablets, USP are an antifibrinolytic drug administered orally. The chemical name is trans-4-aminomethyl-cyclohexanecarboxylic acid. The structural formula is:

Tranexamic acid is a white crystalline powder. It is freely soluble in water and in glacial acetic acid and is very slightly soluble in ethanol and practically insoluble in ether. The molecular formula is C 8H 15NO 2 and the molecular weight is 157.2. 

Tranexamic acid tablets are provided as white to off white oval-shaped tablets debossed with A64 on one side and “˄” on the other side.” The active ingredient in each tablet is 650 mg tranexamic acid. The inactive ingredients contained in each tablet are: colloidal silicon dioxide, croscarmellose sodium, ethyl cellulose, magnesium stearate, microcrystalline cellulose, pregelatinized starch and povidone.

FDA approved dissolution test specifications differ from USP.
A bone shaft or bone joint prosthesis made of a compacted Al2O3 ceramic, cement-free implant. At least one substance capable of releasing bone-growth stimulating ionic material (i.e., lithium ions, boron ions, carbon ions, fluorine ions, sodium ions, magnesium ions, silicon ions, phosphorus ions, potassium ions, calcium ions or mixtures thereof) is incorporated at and near at least a portion of the surface of said Al2O3 implant. The incorporated substance stimulates and controls the attachment of bone tissue to the portions of the surface of implant at the surface locations where the substance is incorporated. The substances can be powdered apatite or apatite-like crystals, such as calcium-aluminum phosphate. A process of preparing the prosthesis which involves placing the substance on at least a portion of the surface of the implant, melting the substance, the substance moving into the affected surface regions of the implant, and cooling the substance to a solid state. Also, a process wherein the implant is inserted into or in contact with a bone or bones; the bone attaching to portions of the surface of the implant which contain the substance - the substance stimulating and controlling the bone attachment.
The investigators will perform a prospective pragmatic randomized effectiveness trial to compare 2 linkage-to-care strategies. Permuted block randomization with 2 strata (i.e., \<40 years of age or active IDU \[defined as IDU within 30 days\], or ≥40 years of age without active IDU) and varying block sizes will be used to minimize imbalance, ensure appropriate numbers of patients in subgroups, and allow for efficient analyses. Allocation will be concealed by blinding block sizes and using the REDCap Randomization Module, a web-based platform to assign patients to arms (REDCap, Vanderbilt University, TN). Although patients will not be blinded to the interventions, they will be blinded to the outcomes. Also, a trained research assistant will perform all enrollment, including stratification and randomization. Clinical staff will not be blinded, however, to assignment.
This experimental non-randomized clinical study is aimed at comparing the efficacy and safety assessment of the proposed topical therapy algorithms using topical glucocorticosteroids and topical calcineurin inhibitors in reducing the severity of atopic dermatitis and the degree of development of transcutaneous sensitization in children of the first year of life. The study included more than 100 children aged 2 to 4 months, who, depending on the decision of the researcher, were divided into two groups. During the period of acute manifestations / exacerbation of atopic dermatitis, patients of both groups received basic therapy, which included the use of a topical glucocorticosteroid (0.1% methylprednisolone aceponate cream) 2 times a day in combination with emollients 2 times a day for 10 days. After the relief of acute inflammatory manifestations, the patients were prescribed proactive therapy, including the use of a topical calcineurin inhibitor or a topical glucocorticosteroid, as a result of which comparison groups were formed. Group No. 1, after the end of basic therapy, received a topical calcineurin inhibitor (1% cream pimecrolimus), which was prescribed in the mode 2 times a day for 3 months, and then in the mode of double application (morning / evening) 3 times a week for up to 1 year. life; Group No. 2 after the end of basic therapy received a topical glucocorticosteroid (methylprednisolone aceponate 0.1%) 2 times a week for 3 months, and then - with exacerbation of AD. Patients of both groups used emollients for a long time in the mode 1-2 times a day. The safety and efficacy of the assigned algorithm was assessed by an investigator at the center. Efficacy was measured using the EASI (Eczema Area and Severity Index) score at screening and then at 6, 9 and 12 months of age. And also by tracking the dynamics of the class and level of sIgE to food (cow's milk protein, chicken egg protein, wheat, soy) and household (hx2 "house dust mixture: Dermatophagoides pteronyssinus, D. farinae, Blatella germanica") allergens using an automated immunological analyzer ImmunoCAP250 (UniCAP System / Phadia AB, Thermo Fisher Scientific, Sweden) at the time of screening and then at 6 and 12 months of age.
BACKGROUND: Quality of life of osteoporosis patients had caused widespread concern, due to high incidence and difficulty to cure. Scale specifics for osteoporosis and suitable for Chinese cultural background lacked. This study aimed to develop an osteoporosis scale in Quality of Life Instruments for Chronic Diseases system, namely QLICD-OS (V2.0).
METHODS: Procedural decision-making approach of nominal group, focus group and modular approach were adopted. Our scale was developed based on experience of establishing scales at home and abroad. In this study, Quality of life measurements were performed on 127 osteoporosis patients before and after treatment to evaluate the psychometric properties. Validity was evaluated by qualitative analysis, item-domain correlation analysis, multi-scaling analysis and factor analysis; the SF-36 scale was used as criterion to carry out correlation analysis for criterion-related validity. The reliability was evaluated by the internal consistency coefficients Cronbach's α, test-retest reliability Pearson correlation r. Paired t-tests were performed on data of ​​the scale before and after treatment, with Standardized Response Mean (SRM) being calculated to evaluate the responsiveness.
RESULTS: The QLICD-OS, composed of a general module (28 items) and an osteoporosis-specific module (14 items), had good content validity. Correlation analysis and factor analysis confirmed the construct, with the item having a strong correlation (most > 0.40) with its own domains/principle components, and a weak correlation (< 0.40) with other domains/principle components. Correlation coefficient between the similar domains of QLICD-OS and SF-36 showed reasonable criterion-related validity, with all coefficients r being greater than 0.40 exception of physical function of SF-36 and physical domain of QLICD-OS (0.24). Internal consistency reliability of QLICD-OS in all domains was greater than 0.7 except the specific module. The test-retest reliability coefficients (Pearson r) in all domains and overall score are higher than 0.80. Score changes after treatment were statistically significant, with SRM ranging from 0.35 to 0.79, indicating that QLICD-OS could be rated as medium responsiveness.
CONCLUSION: As the first osteoporosis-specific quality of life scale developed by the modular approach in China, the QLICD-OS showed good reliability, validity and medium responsiveness, and could be used to measure quality of life in osteoporosis patients.
Participants will receive insulin icodec once weekly for 26 weeks in run-in period to ensure the dose optimization. Thereafter, participants meeting intensification criteria will proceed to the 26-week treatment period to receive once weekly semaglutide subcutaneously starting from 0.25 milligrams (mg) and dose increased up to 1 mg along with 700 units per milliliter (U/mL) insulin icodec therapy. There are no maximum or minimum insulin doses.
This will be the standard of care group. The excision of the non-melanoma skin cancer will be based on standard visual inspection with 4-6mm margins.
An approach for detecting potential medical conditions may be provided. Privacy laws and healthcare regulations may prevent healthcare entities from sharing data or acknowledging even seeing a patient. Secure multi-party computation can allow for the analysis of or more patient's private health data in a secure database. The private health data will only be visible to the health entity which owns or controls the data. Further, a system with oblivious random access memory may be presented which allows for the analysis of one or more patient's multiple private healthcare records. A medical condition diagnosis may be made from the analysis of the multiple private healthcare records by the secure multi-party computation using oblivious random access memory, without divulging information any private healthcare data to unauthorized parties.
PURPOSE: Recent case reports have drawn attention to the emergence of acute pancreatitis, a potentially life-threatening complication associated with tacrolimus. This study uses the Food and Drug Administration Adverse Event Reporting System (FAERS) to investigate the risk signal of acute pancreatitis associated with calcineurin inhibitors (CNIs), with a focus on tacrolimus.
METHODS: We conducted an observational retrospective pharmacovigilance study utilizing the FAERS database, encompassing data from its inception to the third quarter of 2023. The assessment of the association between CNIs and acute pancreatitis was carried out using the Information Component (IC) and Reporting Odds Ratio (ROR). Logistic regression analysis was employed to elucidate factors contributing to fatal outcomes. All analyses were performed using R version 3.2.5.
FINDING: We identified 221 cases of acute pancreatitis linked to CNIs. The median age of individuals experiencing acute pancreatitis induced by tacrolimus was 43, with a predominant occurrence among male patients. Our study showed a significant association between CNIs and acute pancreatitis (ROR 1.82 [1.60-2.08], IC 0.85 [3.66-3.92]). Comparing tacrolimus and cyclosporine, the signal for tacrolimus seemed to be higher. Further analysis revealed that, with the exception of patients aged 60 and above, the signal for tacrolimus remained stable. Contrastingly, the signal for cyclosporine was unstable and limited to the male group and individuals aged less than 20 years. In cases of CNIs-related acute pancreatitis, the mortality rate was 31.67% (70/221 cases). Logistic regression analysis indicated that a younger age acts as a protective factor for death due to CNIs-related acute pancreatitis (OR 0.943, 95% CI 0.915-0.972, P = 0.000).
IMPLICATIONS: Our study has identified a safety signal for tacrolimus in relation to acute pancreatitis. Additionally, we observed advanced age as a significant risk factor for tacrolimus-related acute pancreatitis, leading to mortality. Given the widespread use of tacrolimus, it is crucial for healthcare providers to be vigilant and informed about the potential association with acute pancreatitis.
Procedure 2: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. No buprenorphine will be given beyond day 10.
The Device has the promise of providing a novel mechanism for reducing or preventing the likelihood of TBI, and may be used in conjunction with other protective equipment. TBI is the leading cause of death in individuals under age 45. The cost of TBI in the U.S. is estimated at anywhere from $50 to $150 billion, annually. Concussion in female high school soccer players have been noted to occur at a rate of 4.5 concussions per 10,000 athletic exposures (Comstock, Currie et al. 2015). The investigators propose that Slosh Theory can explain these differences offering a mechanistic approach that could help shed light on further ways to alleviate the TBI burden on society. Note that Slosh Theory teaches that hydrodynamics (fluids moving within moving containers) contribute to, or are even the main etiology for, energy absorption of the cranial contents and that mitigation of SLOSH (increased compensatory reserve volume) may mitigate TBI. Significant morbidity, mortality, and related costs are caused by traumatic brain injury (TBI). A simple, effective, and lightweight device worn by athletes or war fighters in the field, designed to mitigate TBI resulting from blast trauma or concussive events, would save lives, and the huge costs currently being experienced for life-treatment of surviving victims. An externally-worn medical device (the Device) that applies mild jugular vein compression according to the principle of the Queckenstedt Maneuver, is being developed by Q30 Sports Science, LLC (Q30). Preliminary research suggests that the Device has the potential to reduce the likelihood of TBI. The currently developed collar (Smith 2009, Smith and Fisher 2011, Smith and Fisher 2011, Smith 2012) has been approved for studies in humans (IRB 2013-2240) and the results indicate safety for use during high demand and maximal exertion activities. Regarding safety, the externally worn collar is meticulously designed to mimic the body's own omohyoid muscle actions upon the jugular veins that will provide similar pressure and volume increases not to surpass that of a yawn or the mere act of just lying down. Initial safety testing and early clinical trials indicate that the collar application is both safe and efficacious to prevent brain microstructure and neurophysiological changes in response to head impacts.
FIELD: medicine.SUBSTANCE: invention relates to variants of a strain of lactic acid bacteria of the genus Lactobacillus and the use of said strains. Strain of lactic acid bacteria of the genus Lactobacillus DSM 25906, a strain of lactic acid bacteria of the genus Lactobacillus DSM 25907, a strain of lactic acid bacteria of the genus Lactobacillus DSM 25908, a strain of lactic acid bacteria of the genus Lactobacillus DSM 25914, a strain of lactic acid bacteria of the genus Lactobacillus DSM 25915. Said strains coaggregate with at least one pathogenic microorganism Staphylococcus aureus. Disclosed strains, individually or in combination, can be used in antibacterial compositions against Staphylococcus aureus. Said compositions can be used to obtain a pharmaceutical or medical product for the treatment or prevention of skin diseases and diseases of subcutaneous tissue caused by Staphylococcus aureus, or to obtain a cleaning agent or disinfectant for treating surfaces against Staphylococcus aureus, or to obtain a product against Staphylococcus aureus, used in the field of body hygiene, medicinal drugs and prevention, or to obtain a lotion, agitated mixture, powder, hydrogel, cream, "cresa" type agent, ointment, oily ointment or paste for application on the surface of the skin, or to obtain an antibacterial additive that has a specific action against Staphylococcus aureus for the local treatment of skin infections and acceleration of chronic wound healing. Method is also disclosed for identifying and/or selecting said lactic acid bacterium having a property for coaggregation with Staphylococcus aureus.EFFECT: said strains individually or in combination or said compositions can be used as part of a hygiene treatment kit against Staphylococcus aureus.35 cl, 12 dwg, 6 ex
The following relates to medical device technology. In one aspect, a score is calculated based on a patient's vital sign information. The score is displayed in a center circle. Spokes corresponding to individual vital signs may extend from the center circle. The spokes may be color coded based on a subscore (e.g. severity level) of the vital sign that they correspond to. A thickness of each spoke may be based on subscore of the corresponding vital sign.
According to the National Cancer Institute PDQ database, advanced melanoma is refractory to most standard systemic therapy, and all newly diagnosed patients should be considered candidates for clinical trials. Although advanced melanoma is relatively resistant to therapy, several biologic response modifiers and cytotoxic agents have been reported to produce objective responses. Once melanoma is metastatic, treatments are palliative rather than curative. In spite of many attempts at multimodality therapy, the prognosis in this disease remains poor. Further agents are needed if progress is to be made with melanoma treatment.

ATN-224 is an orally active, small molecule that has been shown in cellular and animal models to be antiangiogenic and to have activity against melanoma cell lines. Clinical studies with a similar agent (ammonium tetrathiomolybdate) indicate that the agent can be administered continuously on a daily basis for years in some patients. ATN-224 has the potential to affect the progression of melanoma by mechanisms that include both antiangiogenic and antitumor pathways. Temozolomide, a commonly used agent for melanoma, also has a tolerable profile.
NEW MATERIAL:The compound of formula I [R1 is 1-20C alkyl; R2 is H or lower alkyl; X is group of formula -C(=O)-O- or -O-C(=O)-]. EXAMPLE:Butoxycarbonylmethylprostaglandin I2 ester. USE:Useful as a remedy for arteriosclerosis, cardiac insufficiency and thrombosis. Since the compound can be converted easily to a fat emulsion, it is preferable to use the compound by emulsifying with a vegetable oil (e.g. soybean oil, cottonseed oil, etc.). PREPARATION:The compound of formula I (X is -COO-) can be prepared by reacting prostaglandin I2 (usually its alkali metal salt) with the ester compound of formula II (Xa is halogen) in a solvent such as alcohol, THF, etc. at about 0 deg.C-room temperature. The reaction is preferably carried out in the presence of a phasetransfer catalyst in a solvent such as methylene chloride under anhydrous condition.